Agreement on terminology for Fetal Alcohol Spectrum Disorders

At an historic summit hosted by the National Organization on Fetal Alcohol Syndrome, national experts including for the first time representatives from the Centers for Disease Control, National Institutes of Health, Substance Abuse and Mental Health Services Administration, and Health Canada came together to produce and sign onto a unanimous agreement on terminology for Fetal Alcohol Spectrum Disorders (FASD).

"There is so much confusion around what to call the broader effects of prenatal alcohol exposure when a diagnosis of Fetal Alcohol Syndrome cannot be made," said summit co-chair Dr. José Cordero, Director of the National Center on Birth Defects and Developmental Disabilities. "Acceptance of this new terminology will go a long way toward getting individuals with the wide range of Fetal Alcohol Spectrum Disorders the recognition, treatment, and services they need."

Summit participants stressed the importance of having a term that communicates the range of issues surrounding Fetal Alcohol Syndrome. "The terminology should serve the individual with the disorder, their parents and those who seek services for the affected individual," said summit co-chair Dr. Kenneth Warren, Office of Scientific Affairs Director, National Institute of Alcohol Abuse and Alcoholism. NOFAS Chairman, Terry Lierman, expanded on this by saying, "Our chief concern is that parents, families, and public policy officials speak with one voice when it comes to treatment and prevention."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption